Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Expression of Osteoblast-Specific Factor 2 (OSF-2, Periostin) Is Associated with Drug Resistance in Ovarian Cancer Cell Lines.

Sterzyńska K, Kaźmierczak D, Klejewski A, Świerczewska M, Wojtowicz K, Nowacka M, Brązert J, Nowicki M, Januchowski R.

Int J Mol Sci. 2019 Aug 13;20(16). pii: E3927. doi: 10.3390/ijms20163927.

3.

PTPRK Expression Is Downregulated in Drug Resistant Ovarian Cancer Cell Lines, and Especially in ALDH1A1 Positive CSCs-Like Populations.

Świerczewska M, Sterzyńska K, Wojtowicz K, Kaźmierczak D, Iżycki D, Nowicki M, Zabel M, Januchowski R.

Int J Mol Sci. 2019 Apr 25;20(8). pii: E2053. doi: 10.3390/ijms20082053.

4.

Mutual Expression of ALDH1A1, LOX, and Collagens in Ovarian Cancer Cell Lines as Combined CSCs- and ECM-Related Models of Drug Resistance Development.

Sterzyńska K, Klejewski A, Wojtowicz K, Świerczewska M, Nowacka M, Kaźmierczak D, Andrzejewska M, Rusek D, Brązert M, Brązert J, Nowicki M, Januchowski R.

Int J Mol Sci. 2018 Dec 23;20(1). pii: E54. doi: 10.3390/ijms20010054.

5.

Myotilin, a New Topotecan Resistant Protein in Ovarian Cancer Cell Lines.

Sterzyńska K, Klejewski A, Wojtowicz K, Świerczewska M, Nowicki M, Brązert J, Januchowski R.

J Cancer. 2018 Oct 22;9(23):4413-4421. doi: 10.7150/jca.27342. eCollection 2018.

6.

The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell Lines.

Sterzyńska K, Klejewski A, Wojtowicz K, Świerczewska M, Andrzejewska M, Rusek D, Sobkowski M, Kędzia W, Brązert J, Nowicki M, Januchowski R.

Int J Mol Sci. 2018 Sep 25;19(10). pii: E2901. doi: 10.3390/ijms19102901.

7.

New and Old Genes Associated with Primary and Established Responses to Paclitaxel Treatment in Ovarian Cancer Cell Lines.

Świerczewska M, Klejewski A, Brązert M, Kaźmierczak D, Iżycki D, Nowicki M, Zabel M, Januchowski R.

Molecules. 2018 Apr 12;23(4). pii: E891. doi: 10.3390/molecules23040891.

8.

Analysis of defective protein ubiquitylation associated to adriamycin resistant cells.

Lang V, Aillet F, Xolalpa W, Serna S, Ceccato L, Lopez-Reyes RG, Lopez-Mato MP, Januchowski R, Reichardt NC, Rodriguez MS.

Cell Cycle. 2017;16(24):2337-2344. doi: 10.1080/15384101.2017.1387694. Epub 2017 Nov 20.

9.

The significance of lumican expression in ovarian cancer drug-resistant cell lines.

Klejewski A, Sterzyńska K, Wojtowicz K, Świerczewska M, Partyka M, Brązert M, Nowicki M, Zabel M, Januchowski R.

Oncotarget. 2017 Aug 10;8(43):74466-74478. doi: 10.18632/oncotarget.20169. eCollection 2017 Sep 26.

10.

New and Old Genes Associated with Primary and Established Responses to Cisplatin and Topotecan Treatment in Ovarian Cancer Cell Lines.

Świerczewska M, Klejewski A, Wojtowicz K, Brązert M, Iżycki D, Nowicki M, Zabel M, Januchowski R.

Molecules. 2017 Oct 13;22(10). pii: E1717. doi: 10.3390/molecules22101717.

11.

Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell lines.

Januchowski R, Sterzyńska K, Zawierucha P, Ruciński M, Świerczewska M, Partyka M, Bednarek-Rajewska K, Brązert M, Nowicki M, Zabel M, Klejewski A.

Oncotarget. 2017 Jul 25;8(30):49944-49958. doi: 10.18632/oncotarget.18278.

12.

vPARP Adjusts MVP Expression in Drug-resistant Cell Lines in Conjunction with MDR Proteins.

Wojtowicz K, Januchowski R, Nowicki M, Zabel M.

Anticancer Res. 2017 Jun;37(6):3015-3023.

PMID:
28551640
13.

New and Old Genes Associated with Topotecan Resistance Development in Ovarian Cancer Cell Lines.

Klejewski A, Świerczewska M, Zaorska K, Brązert M, Nowicki M, Zabel M, Januchowski R.

Anticancer Res. 2017 Apr;37(4):1625-1636.

PMID:
28373423
14.

Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines.

Januchowski R, Sterzyńska K, Zaorska K, Sosińska P, Klejewski A, Brązert M, Nowicki M, Zabel M.

J Ovarian Res. 2016 Oct 18;9(1):65.

15.

Increased Expression of Several Collagen Genes is Associated with Drug Resistance in Ovarian Cancer Cell Lines.

Januchowski R, Świerczewska M, Sterzyńska K, Wojtowicz K, Nowicki M, Zabel M.

J Cancer. 2016 Jun 25;7(10):1295-310. doi: 10.7150/jca.15371. eCollection 2016.

16.

Effect of brefeldin A and castanospermine on resistant cell lines as supplements in anticancer therapy.

Wojtowicz K, Januchowski R, Sosińska P, Nowicki M, Zabel M.

Oncol Rep. 2016 May;35(5):2896-906. doi: 10.3892/or.2016.4656. Epub 2016 Mar 7.

PMID:
26985570
17.

Inhibition of protein glycosylation reverses the MDR phenotype of cancer cell lines.

Wojtowicz K, Januchowski R, Nowicki M, Zabel M.

Biomed Pharmacother. 2015 Aug;74:49-56. doi: 10.1016/j.biopha.2015.07.001. Epub 2015 Jul 31.

PMID:
26349962
18.

Microarray-based detection and expression analysis of extracellular matrix proteins in drug‑resistant ovarian cancer cell lines.

Januchowski R, Zawierucha P, Ruciński M, Zabel M.

Oncol Rep. 2014 Nov;32(5):1981-90. doi: 10.3892/or.2014.3468. Epub 2014 Sep 9.

PMID:
25199881
19.

Drug transporter expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line.

Januchowski R, Zawierucha P, Ruciński M, Andrzejewska M, Wojtowicz K, Nowicki M, Zabel M.

Biomed Pharmacother. 2014 May;68(4):447-53. doi: 10.1016/j.biopha.2014.02.002. Epub 2014 Apr 18.

PMID:
24814220
20.

Extracellular matrix proteins expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line.

Januchowski R, Zawierucha P, Ruciński M, Nowicki M, Zabel M.

Biomed Res Int. 2014;2014:365867. doi: 10.1155/2014/365867. Epub 2014 Apr 3.

Supplemental Content

Loading ...
Support Center